SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2011 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Rocky9 who wrote (234)7/9/2011 2:25:26 PM
From: mcbio  Respond to of 400
 
It's funny because I actually own ICGN in my real portfolio and would not consider VRUS at its current valuation in a real portfolio. ARRY is the one stock that could make a difference for me in the competition (and in my real portfolio) provided their Phase 2 MEK combo data reads out positive later this year.



To: Rocky9 who wrote (234)7/9/2011 5:35:58 PM
From: biofisher  Respond to of 400
 
I guess Dew is right. I should have had 20% each in ICGN and ARIA rather than 5%/10%. (assuming they made the cut, of course.)



To: Rocky9 who wrote (234)7/14/2011 11:04:53 AM
From: Rocky9  Read Replies (1) | Respond to of 400
 
And ICGN is blowing out, so there may not be much of a competition.



To: Rocky9 who wrote (234)11/21/2011 9:28:39 AM
From: Rocky9  Read Replies (1) | Respond to of 400
 
"Looks like a competition between:

ICGN (GENE)
VRUS (MCBIO)
ARIA (ROCKY/FIB)"

Did not look like a very good prediction for awhile, but looks like Mcbio now.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News